Table 1.
Baseline characteristics of the study population among those with baseline coronary artery calcium 0, stratified by development of incident atherosclerotic cardiovascular disease
| Incident ASCVD | |||
|---|---|---|---|
| No (N= 3,212) | Yes (N= 189) | p-value | |
| Age | 58 (9) | 61 (9) | <0.001 |
| Sex | |||
| Women | 2,047 (64%) | 109 (58%) | 0.09 |
| Men | 1,165 (36%) | 80 (42%) | |
| Race/Ethnicity | 0.06 | ||
| White | 1,068 (33%) | 56 (30%) | |
| Chinese-American | 386 (12%) | 13 (7%) | |
| Black | 992 (31%) | 70 (37%) | |
| Hispanic American | 766 (24%) | 50 (26%) | |
| Graduate or professional school | 587 (18%) | 28 (15%) | 0.15 |
| Presence of health insurance | 2,847 (89%) | 165 (88%) | 0.61 |
| Cigarette smoking status | <0.001 | ||
| Never | 1,811 (57%) | 84 (45%) | |
| Former | 983 (31%) | 60 (32%) | |
| Current | 406 (13%) | 44 (23%) | |
| Diabetes mellitus | 279 (9%) | 35 (19%) | <0.001 |
| Hypertension | 1,545 (48%) | 124 (66%) | <0.001 |
| Systolic BP, mm Hg | 122 (20) | 131 (23) | <0.001 |
| Aspirin use | 428 (14%) | 33 (18%) | 0.13 |
| Statin use | 306 (10%) | 21 (11%) | 0.47 |
| Waist circumference, cm | 96.5 (14.8) | 99.1 (14.6) | 0.02 |
| Family history of premature ASCVD | 468 (18%) | 34 (23%) | 0.13 |
| Chronic kidney disease | 440 (14%) | 43 (23%) | 0.001 |
| HDL-C, mg/dL | 53 (15) | 50 (14) | 0.01 |
| Triglycerides, mg/dL | 116 (31) | 115 (31) | 0.54 |
| LDL-C, mg/dL | 126 (81) | 138 (133) | 0.07 |
| *Lp(a), mg/dL | 18.2 (7.6–40.8) | 18.4 (8.4–47.0) | 0.70 |
| *hsCRP, mg/L | 1.92 (0.82–4.26) | 2.55 (0.86–4.99) | 0.06 |
| 10-year ASCVD risk, % | 4.84 (2.05–10.68) | 10.68 (4.61–18.77) | <0.001 |
| <7.5% | 2,022 (63%) | 65 (34%) | |
| 7.5%–<15% | 646 (20%) | 60 (32%) | |
| 15%–<20% | 199 (6%) | 17 (9%) | |
Continuous variables are summarized as mean (standard deviation) or median (interquartile range)* as appropriate. Categorical variables are summarized as count (percentage)
Abbreviations: BP (blood pressure); CHD (coronary heart disease); HDL-C (high-density lipoprotein cholesterol); LDL-C (low-density lipoprotein cholesterol); Lp(a) (lipoprotein (a)); hsCRP (high-sensitivity C-reactive protein); ASCVD (atherosclerotic cardiovascular disease)